RM-1929 PIT, which uses cetuximab sarotalocan sodium, an antibody targeting EGFR conjugated with a light-activatable dye, combined with a laser system to target only tumor cells, is emerging as an important treatment strategy for recurrent HNSCC. Here, EGFR is linked to head and neck squamous cell carcinoma.